Navigation Links
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Date:9/24/2009

"non-culprit" lesions of the three-vessel coronary tree. Half of the patients treated for non-culprit events exemplified the classic notion of vulnerable plaque.

The event rate, particularly that attributed to vulnerable plaques specifically, was lower than expected. Further, patients who experienced "non-culprit" events in the years following PCI were more likely to present with progressive or unstable angina, and rarely with cardiac death, arrest or MI. Imaging of the lesions that did progress to events suggests that vulnerable plaque lesions with a large plaque burden and large necrotic core without a visible cap were at especially high risk for future adverse cardiovascular events.

"Abbott's PROSPECT trial is the most comprehensive study ever done on vulnerable plaque and the results shed new light on understanding its role in the progression of coronary artery disease," said John M. Capek, executive vice president, medical devices, Abbott. "As a leader in cardiovascular devices, diagnostics and medicines, Abbott looks forward to sharing these results with the vascular community and adding to our understanding of the disease."

About the PROSPECT Trial

Abbott's PROSPECT trial is the first prospective natural history study to examine the role of vulnerable plaque and how it might progress to a cardiac event. PROSPECT used novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.

PROSPECT enrolled 700 patients from 40 clinical centers across the United States and Europe. All patients received PCI for acute coronary syndrome (ACS), which included unstable angina, NSTEMI or STEMI. Patient follow up continued for three years. Abbott sponso
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 28, 2015 ... has announced the addition of the "United ... report to their offering.      ... medical adhesives in the United States ... through 2020 Medical device manufacturers ...
(Date:5/28/2015)... THE WOODLANDS, Texas , May 28, 2015 /PRNewswire/ ... announced today that Lexicon management will present at the ... at 8:00 a.m. Eastern Time in New ... of Lexicon,s clinical development programs and milestones. ... Lexicon,s website at www.lexpharma.com . An archived version ...
(Date:5/28/2015)... 28, 2015  Transportation Insight, a leading ... the SDCE100 Award for the second consecutive ... Executive magazine. Transportation Insight was chosen ... quantify and control supply chain costs associated ... market. Deploying Transportation Insight,s Enterprise Logistics solution ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3Lexicon To Present At The Jefferies 2015 Healthcare Conference 2Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 2Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 3Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 4
... LAKE GENEVA, Wis., Jan. 4, 2012 "My philosophy in ... so they can fully achieve their goals," mentions Robert ... Walworth Hospital and Medical Center in Lake Geneva, Wisconsin ... Dr. Paresi recently joined Mercy Health System with the ...
... PHOENIX, Jan. 4, 2012   Kedem Pharmaceuticals Inc. ... sublingual drug delivery is pleased to announce that it ... compliant formulation development company, Corealis Pharma, Inc. for the ... the Company,s second lead therapeutic drug. The KDM-1102 drug ...
Cached Medicine Technology:Fulfill New Year Resolutions with Cosmetic Surgery 2Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials 2Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials 3
(Date:5/28/2015)... 2015 Park Cities Pet Sitter is offering ... class starting Saturday, June 6th at 10:30am. The ... McCommas Blvd in Dallas, with a maximum of six dogs ... five weeks, with no class being held over the 4th ... , In this Intermediate-to-Advanced level class, dogs will solidify their ...
(Date:5/28/2015)... Three years ago, Dr. Jeffrey Gosin announced that ... & Vein Center! Dr. Gosin’s center is focused ... his mission to provide the highest quality care in a ... Jeffrey Gosin is Board Certified in Surgery and Vascular Surgery. ... Jefferson Medical College. He completed a General Surgery residency at ...
(Date:5/28/2015)... Lanham, Md. (PRWEB) May 28, 2015 ... Weekend Sweepstakes grand prize winner Robert Davis of Newark, ... Davis to congratulate him on winning the $10,000 sweepstakes ... winners from over 100,000 entries from around the country ... prize. The drawing took place on May 21 at ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... ISMETT , a leading transplant hospital ... Sicilian economy by €132.5 million in expenditure in 2013, generated ... than €73 million by retaining patients who otherwise would have ... study by the Battelle Memorial Institute. At the same time, ... advanced health care management that is transforming Sicily into a ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3
... patients also leads to higher costs, study finds , ... acid reducer greatly increases the risk of pneumonia in ... found. , Researchers at Wake Forest University School of ... cardiothoracic surgery patients on breathing machines who were given ...
... WASHINGTON, Sept. 18 In response to the release ... Baucus, DMLR Chairman Stuart L. Weinstein, M.D. issued the following statement: ... is inadequate in addressing the serious problems caused by medical lawsuit ... care policy experts, opinion leaders, and patients all across the country ...
... , WEINER,S NEW YORK TIMES LETTER TODAY REFUTES ... Sept. 18 The Public Option is still viable as the House ... York Times) nor on ,life support, (ABC News)," says Robert Weiner, former Chief ... spokesman for the White House National Drug Policy Office. , , ...
... , , , ... Isotopes Inc. (OTC Bulletin Board: INIS) announces the successful conclusion ... and major shareholders. , , International Isotopes ... September 18, 2009 for just under $1 million. In ...
... LAKE SUCCESS, N.Y., Sept. 18 IPRO ... dissemination of tools and research findings aimed at improving ... United States. Under the Agency for Healthcare Research and ... task assignments to support accelerated dissemination of evidence-based products ...
... , CABOT, Vt., Sept. 18 Imagine if you ... Vegas without leaving your neighborhood! Well, that,s exactly what more than ... their way daily through Cabot Creamery Cooperative,s Vermont-to-Vegas Challenge. ... ) , , Participants competed online -- via ...
Cached Medicine News:Health News:Ulcer Preventative May Raise Pneumonia Risks 2Health News:Statement From Stuart L. Weinstein, MD, Chairman, Doctors for Medical Liability Reform on Senator Baucus' Health Care Reform Proposal 2Health News:Public Option Still Viable As House Set to Pass It -- Not 'Fading,' Says Robert Weiner, Former House Aging Committee Director 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 3Health News:IPRO Wins Knowledge Transfer/Implementation Federal Contract From AHRQ 2Health News:Cabot(R) Creamery Cooperative's Vermont-To-Vegas Virtual Challenge Ends On A Healthy Note 2Health News:Cabot(R) Creamery Cooperative's Vermont-To-Vegas Virtual Challenge Ends On A Healthy Note 3
... Made with elastic fabric, these head ... you need to begin testing. Each Electro-Cap ... to the International 10-20 System. When you ... you are using with your head cap ...
... implant was conceived by Arthur C. Perry, ... comprehensive review of the literature on orbital ... back to 1885 (Mules 1885). This review, ... performance of contemporary implants, allowed Perry to ...
... Spheres for Enucleation and Evisceration. ... combine the structure of standard MEDPOR ... mixture. The Bioglass component, mixed throughout ... fibrovascular ingrowth into the MEDPOR PLUS ...
... ICL and the TORIC ICL are posterior ... STAARs proprietary collagen copolymer, the lens rests ... This unique material contains a small amount ... superior optical capability. The lens is gently ...
Medicine Products: